Wechalekar, A, Antoni, G, Al Azzam, W, Bergström, M, Biswas, S, Chen, C, Cheriyan, J, Cleveland, M, Cookson, L, Galette, P, Janiczek, R L, Kwong, R Y, Lukas, M A, Millns, H, Richards, D, Schneider, I, Solomon, S D, Sörensen, J, Storey, J, Thompson, D, van Dongen, G, Vugts, D J, Wall, A, Wikström, G & Falk, R H 2022, ' Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis : an open-label Phase 2 study and an adjunctive immuno-PET imaging study ', BMC Cardiovascular Disorders, vol. 22, no. 1, 49 . https://doi.org/10.1186/s12872-021-02407-6 BMC Cardiovascular Disorders, 22(1). BioMed Central BMC Cardiovascular Disorders, 22(1):49. BioMed Central